Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M26,790Revenue $M7,876Net Margin (%)11.1Altman Z-Score2.1
Enterprise Value $M35,064EPS $2.2Operating Margin %16.2Piotroski F-Score6
P/E(ttm)25.1Beneish M-Score-2.2Pre-tax Margin (%)11.2Higher ROA y-yY
Price/Book3.010-y EBITDA Growth Rate %12.4Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %8.3Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow55.9y-y EBITDA Growth Rate %10.3ROA % (ttm)5.2Higher Current Ratio y-yN
Dividend Yield %--PEG3.1ROE % (ttm)19.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M490ROIC % (ttm)9.8Gross Margin Increase y-yY

Gurus Latest Trades with MYL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYLJoel Greenblatt 2015-03-31 Reduce-0.3%$52.74 - $64.96
($57.01)
$ 54.67-4%Reduce 97.62%16,021
MYLVanguard Health Care Fund 2015-03-31 Add0.11%$52.74 - $64.96
($57.01)
$ 54.67-4%Add 5.68%15,891,898
MYLFirst Eagle Investment 2015-03-31 Reduce-0.04%$52.74 - $64.96
($57.01)
$ 54.67-4%Reduce 30.38%586,016
MYLJohn Paulson 2014-12-31 Add0.72%$46.5 - $58.62
($53.92)
$ 54.671%Add 19.64%14,948,400
MYLJoel Greenblatt 2014-12-31 Buy 0.31%$46.5 - $58.62
($53.92)
$ 54.671%New holding673,287
MYLVanguard Health Care Fund 2014-12-31 Reduce-0.05%$46.5 - $58.62
($53.83)
$ 54.672%Reduce 2.64%15,037,080
MYLFirst Eagle Investment 2014-12-31 Add$46.5 - $58.62
($53.83)
$ 54.672%Add 3.97%841,779
MYLVanguard Health Care Fund 2014-09-30 Add1.24%$44.97 - $52.34
($48.56)
$ 54.6713%Add 223.41%15,444,880
MYLFirst Eagle Investment 2014-09-30 Reduce-0.06%$44.97 - $52.34
($48.56)
$ 54.6713%Reduce 34.81%809,603
MYLMario Gabelli 2014-09-30 Reduce$44.97 - $52.34
($48.56)
$ 54.6713%Reduce 27.54%10,000
MYLFirst Eagle Investment 2014-06-30 Add0.07%$45.72 - $52.1
($49.11)
$ 54.6711%Add 83.88%1,241,991
MYLFirst Eagle Investment 2014-03-31 Buy 0.09%$42.26 - $57.2
($48.38)
$ 54.6713%New holding675,428
MYLJoel Greenblatt 2014-03-31 Sold Out -0.01%$42.26 - $57.2
($48.38)
$ 54.6713%Sold Out0
MYLDavid Dreman 2014-03-31 Sold Out $42.26 - $57.2
($48.38)
$ 54.6713%Sold Out0
MYLJoel Greenblatt 2013-12-31 Reduce$37.865 - $44.5
($41.09)
$ 54.6733%Reduce 31.83%7,291
MYLDavid Dreman 2013-12-31 Buy $37.865 - $44.5
($41.09)
$ 54.6733%New holding1,221
MYLJoel Greenblatt 2013-09-30 Reduce-0.16%$30.37 - $38.95
($35.23)
$ 54.6755%Reduce 91.73%10,695
MYLJohn Paulson 2013-06-30 Reduce-0.98%$27.96 - $31.87
($29.87)
$ 54.6783%Reduce 32.83%12,139,300
MYLJoel Greenblatt 2013-06-30 Add0.15%$27.96 - $31.87
($29.87)
$ 54.6783%Add 668.47%129,295
MYLVanguard Health Care Fund 2013-06-30 Add0.07%$27.96 - $31.87
($29.87)
$ 54.6783%Add 14.36%4,775,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYL is held by these investors:


News about MYL:

Articles On GuruFocus.com
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Tom Russo Buys 3 New Stocks in Q1 May 18 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 

More From Other Websites
Will Keryx (KERX) Miss Estimates This Earnings Season? - Analyst Blog Aug 04 2015
Will Mylan (MYL) Beat Q2 Earnings on New Product Sales? - Analyst Blog Aug 04 2015
Pfizer Inc. Earnings Analysis: By the Numbers Q2*, 2015 Aug 04 2015
Will Endocyte (ECYT) Earnings Surprise Investors in Q2? - Analyst Blog Aug 03 2015
The 7 Most Important Earnings in the Week Ahead Aug 02 2015
Teva Proves Its Decade-Hold Status With Massive Funding Jul 31 2015
Mylan Inc. -- Moody's Affirms Mylan's Baa3; outlook changed to negative from developing Jul 31 2015
Mylan Is the Lone Underperformer in IBB’s Top 10 Jul 31 2015
Analysts ask if Mylan can make case with its shareholders for Perrigo purchase Jul 29 2015
Mylan gets EU clearance for Perrigo clearance Jul 29 2015
Mylan gets European clearance in proposed Perrigo takeover Jul 29 2015
Mylan gets European clearance in proposed Perrigo takeover Jul 29 2015
Abbott Laboratories Earnings Analysis: By the Numbers Jul 29 2015
Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of... Jul 29 2015
EU clears acquisition of Perrigo by Mylan Jul 29 2015
More tie-ups in generic drug cos expected Jul 28 2015
Amgen Stock Clears Buy Point Ahead Of Earnings Jul 28 2015
Mylan selloff draws bullish trades Jul 28 2015
There's 'Life After Teva' For Mylan, Says Leerink Jul 28 2015
BMO Ups Teva To Buy; Allergan Deal 'Solidifies Leadership' In Generics Jul 28 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK